Local view for "http://purl.org/linkedpolitics/eu/plenary/2006-06-13-Speech-2-017"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2006-06-13"^^xsd:date2
dcterms:Is Part Of	lp_eu:Seventh framework programme – Nuclear research and training activities (2007-2011) (debate)2
dcterms:Language	"lt"^^xsd:language2
lpv:document identification number	"en.20060613.6.2-017"2
lpv:hasSubsequent	lp_eu:2006-06-13-Speech-2-0182
lpv:speaker	lp:Aloyzas Sakalas2
lpv:spokenAs	member; JURI (2004-07-21--2007-01-14)3 unknown; Lietuvos socialdemokratų partija (2004-07-20--2009-07-13)3 member; Delegation for relations with Belarus (2004-09-15--2007-03-11)3 member; PES (2004-07-20--2009-07-13)3 substitute; AFET (2004-07-21--2007-01-14)3
lpv:translated text	". The Committee on Legal Affairs has considered the ethical questions surrounding the use of embryonic stem cells. Embryonic stem cells differ from ordinary stem cells in that they are not yet differentiated, and therefore, any component of the human organism can be grown from them. In compiling the opinion of the committee, I have given two ethical positions: 1) to use embryonic stem cells to treat such incurable diseases as diabetes, Parkinson's disease, infarcted myocardium, etc. This would help prevent premature death in adults, but the embryo itself would die 2) to protect the embryo, but take away last hope from people suffering from incurable diseases. A majority of the Committee voted in favour of the second position. I am personally pleased that the Committee on Industry, Research and Energy has found a compromise and has submitted appropriate amendments, which I propose that we approve."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph